Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of LY2623091 in Chronic Kidney Disease
NCT01427972Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LY-2623091 in chronic kidney disease (CKD), sponsored by Eli Lilly and Company. Started Sep 2011; status: completed.
02
Drugs
LY-2623091
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT01427972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01427972.